A novel research infrastructure enabling life-course studies of healthy aging

点击翻译按钮获取中文摘要

ABSTRACT for transition to R33 Phase This proposal will enhance a unique scientific resource that will facilitate valid life-course approaches to define the ideal path to successful aging, leveraging decades of NIH investment and allowing exploration of new hypotheses. This resource will complement data from longitudinal studies with less coverage of early life, thereby advancing the science of successful aging and providing evidence to enable remote assessment of aging-related outcomes, which can then be applied to other cohorts. Specific aims for the enhanced and expanded activities phase (R33) are to demonstrate feasibility and define the best methods for remotely assessing aging-related factors in dispersed epidemiologic cohorts by: Aim #1: Conducting interviews and administering questionnaires to assess mid-life cognitive function, social isolation, multiple chronic conditions, quality of life, functional independence, and physical performance using validated questionnaires and tools, including NIH Toolbox and PROMIS assessments; and Aim #2: Testing the feasibility and validity of assessing risk factor data using mobile technology in an in-home setting. We will evaluate whether remote sample collection (e.g., saliva, stool), physiologic assessments (e.g., heart rate, blood labs, ECG, pulse-wave velocity), objectively-measured lifestyle factors (e.g., physical activity, sleep) and dietary intake assessed by in-home mobile technology produce high- quality research data, compared with the gold standard of in-person visits. To achieve Aim #1, we will identify a random sample of 150 participants from each cohort already participating in the i3C Outcomes study wi ll be contacted by phone, mail and/or email. The research coordinator will obtain consent and will be trained to administer the assessments. The responses will be entered into a study-specific REDCap database, a HIPAA- compliant web-based database available at both Tulane and CCHMC. We aim to recru it subjects with multiple data points across childhood and adulthood, who will have decades of participation. To achieve Aim #2, each cohort will enroll 50 participants (150 total) at the time of phone interview (R33 Aim 1) to participate in an additional feasibility study of wearable technology, and an in-person validation visit. Subjects will be selected by proximity to the clinic site, access to a smartphone, sex (50% male), and race (based on proportion in each cohort). During this phone call, additional consent procedures will be explained, and the in-person validation study visit will be scheduled for the week following the home data collection. A Virtual Clinic study kit will be mailed, along with a paper consent. All participants receiving the mailed in-home devices wil l be scheduled for an in-person clin ic visit at Tulane or CCHMC during the next 1-2 weeks after the in-home testing. During this visit, participants will undergo the following assessments, which will be used to validate the measurements from the in-home devices or the telephone/questionnaire assessments from Aim 1. Milestones and ti meline for R33 phase are presented in the Table below. Deliverables from the R33 phase include: (1) Recruit 450 subjects (150 per cohort) for telephone interviews; (2) Complete in-home and in-person assessments of mobile technology on 150 subjects (50/cohort); and (3) Evaluation of feasibility, acceptabi lity, validity and data quality.